← Back to Clinical Trials
Recruiting NCT04460313

NCT04460313 Nasopharyngeal Carriage of S. Pneumoniae

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04460313
Status Recruiting
Phase
Sponsor Association Clinique Thérapeutique Infantile du val de Marne
Condition Nasopharyngeal Carriage
Study Type INTERVENTIONAL
Enrollment 25,760 participants
Start Date 2001-09-11
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 6 Months
Max Age 15 Years
Study Type INTERVENTIONAL
Interventions
nasopharyngeal sample (mandatory)Stools collection or anorectal swab samples (optional)nasopharyngeal sample (optional)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 25,760 participants in total. It began in 2001-09-11 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This nasopharyngeal (NP) carriage surveillance study was requested by the European Agency for the Evaluation of Medicinal Products as a post-licensing commitment to determine whether the use of the pneumococcal conjugate vaccines (PCVs) including 7 then 13 valents (introduced in 2001 and 2010, respectively) caused a shift in the distribution of Streptococcus pneumoniae serotypes in children with acute otitis media and modified the resistance of this bacterial species to antibiotics.

Eligibility Criteria

children seen on an outpatient Inclusion Criteria: * both sexes * suffering from suppurative AOM or healthy children * age: 6 months to 36 months for AOM * age: 6 months to 15 years for healthy children * informed consent from parents or guardians * Children who haven't received antibiotic treatment within 7 days before enrollment, Exclusion Criteria: * severe underlying disease, * inclusion in the study during the previous 12 months * Children with bullous myringitis cannot be included.

Contact & Investigator

Central Contact

Corinne Levy, MD

✉ corinne.levy@activ-france.fr

📞 0033148850404

Principal Investigator

Robert Cohen, MD

PRINCIPAL INVESTIGATOR

Association Clinique Thérapeutique Infantile du val de Marne

Frequently Asked Questions

Who can join the NCT04460313 clinical trial?

This trial is open to participants of all sexes, aged 6 Months or older, up to 15 Years, studying Nasopharyngeal Carriage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04460313 currently recruiting?

Yes, NCT04460313 is actively recruiting participants. Contact the research team at corinne.levy@activ-france.fr for enrollment information.

Where is the NCT04460313 trial being conducted?

This trial is being conducted at Créteil, France.

Who is sponsoring the NCT04460313 clinical trial?

NCT04460313 is sponsored by Association Clinique Thérapeutique Infantile du val de Marne. The principal investigator is Robert Cohen, MD at Association Clinique Thérapeutique Infantile du val de Marne. The trial plans to enroll 25,760 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology